| (CNW) TSO3 Receives 2017 Purchase Orders from Getinge Backlog for the STERIZONE(R) VP4 Sterilizer Exceeds $18 Million QUBEC CITY, Dec. 2, 2016 /CNW Telbec/ - TSO(3) Inc. (TSX: TOS) ("TSO(3) " or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has received initial purchase orders from Getinge USA, Inc., for fiscal 2017. These orders will increase the rate of production and throughput from the Company's assembly facility in Quebec throughout 2017. The purchase orders were received in association with the distribution agreement signed with Getinge in November 2015. "This PO from Getinge provides a degree of operational predictability for 2017 as it enables TSO(3) to leverage supply chain improvements achieved in fiscal 2016," said R.M. (Ric) Rumble, TSO(3) 's President and CEO. "We look forward to further collaboration and success as we enter our second year of this strategic partnership. TSO(3) , together with Getinge continue to collaborate and deploy an increasing number of sterilizers and deliver on our vision -- Creating the Improved Standard in Healthcare Sterile Reprocessing(TM)." About the STERIZONE(R) VP4 Sterilizer The STERIZONE(R) VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H(2) O(2) ) and ozone (O(3) ) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System(TM) automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines. The STERIZONE(R) VP4 Sterilizer is the only FDA cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. It is also the only terminal sterilization method cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity). Other H(2) O(2) sterilizers are limited to load weights of up to only 25 lb and require dedicated fixed cycles for different types of instruments (reducing overall throughput). More information about the STERIZONE(R) VP4 Sterilizer is available through TSO(3) 's website, under the Products section at https://www.tso3.com/en/products/sterizone-vp4/. About TSO(3) Founded in 1998, TSO(3) 's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO(3) also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. TSO(3) announced in July 2016 that it received FDA clearance in the U.S. for extended claims relating to the terminal sterilization of multi-channel flexible endoscopes. The FDA clearance of additional claims represents an entirely new level of patient protection against ineffective device reprocessing resulting from the use of less robust systems like high-level disinfection, particularly for video colonoscopes and gastroscopes. For more information about TSO(3) , visit the Company's web site at www.tso3.com. The statements in this release and oral statements made by representatives of TSO(3) relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO(3) 's sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearance to market its products on a worldwide basis; general business and economic conditions, the condition of the financial markets, the ability of TSO(3) to obtain financing on favourable terms and other risks and uncertainties. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful. SOURCE TSO3 Inc. /CONTACT: Company Contacts: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, info@tso3.com; TSO3 Inc., Glen Kayll, CFO, Tel: 418 651-0003, info@tso3.com; Investor Relations: Liolios Group, Inc., Ron Both, Tel: 949 574-3860, TOS@liolios.com; Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, bmire@renmarkfinancial.com /Web site: https://www.tso3.com Copyright CNW Group 2016 (END) |